# An Overview of Managements in Meningiomas **Authors:** Lianhua Zhao, Wei Zhao, Yanwei Hou, Cuixia Wen, Jing Wang, Pei Wu, Zaiyu Guo PMC · DOI: 10.3389/fonc.2020.01523 · 2020-08-21 ## TL;DR This review discusses current and future treatment strategies for meningiomas, which are common brain tumors. ## Contribution The paper provides a comprehensive overview of treatment strategies and highlights ongoing research directions. ## Key findings - Surgery and radiotherapy remain the main treatments for meningiomas. - Systemic therapies like chemotherapy have not been proven effective in large data series. - Ongoing clinical trials are exploring new treatment options for meningiomas. ## Abstract Meningioma is the most frequent primary tumor of the central nervous system. Important advances have been achieved in the treatment of meningioma in recent decades. Although most meningiomas are benign and have a good prognosis after surgery, clinicians often face challenges when the morphology of the tumor is complicated or the tumor is close to vital brain structures. At present, the longstanding treatment strategies of meningioma are mainly surgery and radiotherapy. The effectiveness of systemic therapy, such as chemotherapy or targeted therapy, has not been confirmed by big data series, and some clinical trials are still in progress. In this review, we summarize current treatment strategies and future research directions for meningiomas. ## Linked entities - **Diseases:** meningioma (MONDO:0003057) ## Full-text entities - **Genes:** KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, NF2 (NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor) [NCBI Gene 4771] {aka ACN, BANF, SCH, SWNV, merlin-1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, SST (somatostatin) [NCBI Gene 6750] {aka SMST, SST1}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, IFNA2 (interferon alpha 2) [NCBI Gene 3440] {aka IFN-alpha-2, IFN-alphaA, IFNA, IFNA2B, leIF A}, POLR2A (RNA polymerase II subunit A) [NCBI Gene 5430] {aka NEDHIB, POLR2, POLRA, RPB1, RPBh1, RPO2}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, KLF4 (KLF transcription factor 4) [NCBI Gene 9314] {aka EZF, GKLF}, TRAF7 (TNF receptor associated factor 7) [NCBI Gene 84231] {aka CAFDADD, RFWD1, RNF119}, AR (androgen receptor) [NCBI Gene 367] {aka AIS, AR8, DHTR, HPCX3, HUMARA, HYSP1}, SMO (smoothened, frizzled class receptor) [NCBI Gene 6608] {aka CRJS, FZD11, Gx, PHLS, SMOH}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, RARA (retinoic acid receptor alpha) [NCBI Gene 5914] {aka NR1B1, RAR, RARalpha} - **Diseases:** metastatic (MESH:D000092182), ependymoma (MESH:D004806), III meningiomas (MESH:D008579), died (MESH:D003643), toxicity (MESH:D064420), brain tissue or vascular injury (MESH:D020214), cavernous sinus meningiomas (MESH:D020226), cranial nerve injury (MESH:D020209), brain edema (MESH:D001929), III (MESH:C537189), coagulation (MESH:D001778), GTR (MESH:D000072662), vessel injuries (MESH:C536223), intracranial hemorrhage (MESH:D020300), necrosis (MESH:D009336), vascular injury (MESH:D057772), cerebral infarction (MESH:D002544), WHO grade I meningioma (MESH:D001254), II and III (MESH:C536044), venous infarction (MESH:D020520), ischemic necrosis (MESH:D005271), vasospasm (MESH:D020301), venous sinus (MESH:D012851), PTE (MESH:D004487), nerve injury (MESH:D000080902), occlusion of venous sinuses (MESH:D012852), neurological deficit (MESH:D009461), Tumor (MESH:D009369), internal carotid artery branch embolism (MESH:D002340), anterior skull base meningiomas (MESH:D019292), infection (MESH:D007239), ischemic complications (MESH:D017202), central nervous system tumor (MESH:D016543), Epilepsy (MESH:D004827), seizure (MESH:D012640), bleeding (MESH:D006470), optic nerve (MESH:D000080344), radiation reaction (MESH:D011832), brain tissue (MESH:D001927), occlusion of blood vessels (MESH:D009383), neurological complications (MESH:D002493), postoperative infection (MESH:D013530), cerebral hemorrhage (MESH:D002543), Tuberculum sellae meningiomas (MESH:D004652), brain tumor lesions (MESH:D001932), gliomas (MESH:D005910), pressure (MESH:D003668), invasive tumors (MESH:D009361), hemangioblastoma (MESH:D018325), Cerebrospinal fluid leakage (MESH:D065634), hemangioma (MESH:D006391), intracranial mass (MESH:C536030), calcification (MESH:D002114), visual impairment (MESH:D014786), embolization (MESH:D004617) - **Chemicals:** retinol (MESH:D014801), Irinotecan (MESH:D000077146), Imatinib (MESH:D000068877), oxygen (MESH:D010100), HU (MESH:D006918), Erlotinib (MESH:D000069347), tamoxifen (MESH:D013629), Afureserib (-), bevacizumab (MESH:D000068258), Levetiracetam (MESH:D000077287), PP IX (MESH:C028025), gabapentin (MESH:D000077206), Everolimus (MESH:D000068338), octreotide (MESH:D015282), Fenretinide (MESH:D017313), mifepristone (MESH:D015735), Vatalanib (MESH:C404768), Temsirolimus (MESH:C401859), Gefitinib (MESH:D000077156), 5-ALA (MESH:C000614854), Vismodegib (MESH:C538724), TMZ (MESH:D000077204), Sunitinib (MESH:D000077210) - **Species:** Homo sapiens (human, species) [taxon 9606], herpes virus [taxon 39059] ## Figures 2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC7473392/full.md --- Source: https://tomesphere.com/paper/PMC7473392